Forian completes acquisition, to delist from Nasdaq By Investing.com

Forian completed an all-cash tender offer and merger at $2.17 per share, taking the company private and ending its Nasdaq listing. The buyer parties already owned about 70% of the shares, and the remaining 6.44 million tendered shares were accepted, satisfying the minimum condition. The company also highlighted 50% trailing-twelve-month revenue growth to $30.26 million, though it remains unprofitable.

Analysis

This is less a standalone company event than another data point in a broader capital-allocation unwind: Berkshire is trimming a mature energy bet into strength, which typically signals that upside in the commodity is now less convex than the market assumes. The second-order read-through is negative for incremental buyers of large-cap oil beta: when a high-credibility holder sells into a rally, it can cap enthusiasm for CVX relative to peers with cleaner self-help or higher torque.

FORA is the opposite kind of setup: the tender and delisting remove a small-cap, low-liquidity name from public markets, which usually creates a short-lived technical uplift in the remaining event-driven cohort. That matters for the micro-cap M&A complex because it reinforces the idea that private equity can still harvest public-market discounts in sub-scale software/healthcare/data names, especially where balance-sheet quality avoids financing friction. The broader loser is Nasdaq market quality at the margin: every successful take-private reduces optionality for public investors and strengthens the bid for similar assets.

The key risk on the energy side is timing. If crude keeps rising over the next few weeks, the market may interpret Berkshire’s sale as premature and re-rate other diversified energy holders, but over a 3-6 month horizon, sustained prices usually invite supply response and political pressure that compresses margins. On the deal side, the main catalyst is not the close itself but the post-close vacuum: once FORA is fully off-exchange, any residual arbitrage or special-situation capital tied to it gets redeployed, which can pressure comparable names if the market senses a wave of take-privates.

Contrarian angle: the headline encourages a simplistic 'Berkshire bearish on oil' read, but this is more likely portfolio rebalancing than a macro call. For CVX, the market may be over-discounting the sale as negative, creating a better entry point if integrated majors can maintain buybacks while prices stay firm. For event-driven investors, the better trade is not chasing FORA, but hunting the next under-owned, cash-flow-positive small-cap where a sponsor can pay a meaningful premium before public multiples re-rate.

Key Decisions for Investors

• Fade the knee-jerk weakness in CVX over the next 1-2 sessions: buy on any 1-2% post-headline dip with a 3-6 month horizon, targeting a recovery as the market refocuses on cash return capacity rather than Berkshire's trimming
• Add a pair trade: long XLE / short XLU for 1-3 months if crude remains firm; energy should outperform defensives as earnings revisions expand, but keep a tight stop if oil rolls over
• Avoid chasing FORA post-close; instead, screen for similarly sized, profitable data/vertical SaaS names with low float and clean balance sheets as potential take-private candidates over the next 3-6 months
• If you need event-driven exposure, rotate capital from expired-forced Merger Arb into a basket of small-cap software/healthcare M&A names; the setup improves as dry powder looks for the next public-to-private catalyst
• For upside with defined risk, consider a medium-dated CVX call spread 3-6 months out; the thesis is that Berkshire's sale is not a fundamental earnings inflection, while commodity strength can still support FCF and capital returns